Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Anti-TTR Nanobodies Allow the Identification of TTR Neuritogenic Epitope Associated with TTR-Megalin Neurotrophic Activities.

Gomes JR, Sárkány Z, Teixeira A, Nogueira R, Cabrito I, Soares H, Wittelsberger A, Stortelers C, Macedo-Ribeiro S, Vanlandschoot P, Saraiva MJ.

ACS Chem Neurosci. 2019 Jan 16;10(1):704-715. doi: 10.1021/acschemneuro.8b00502. Epub 2018 Oct 23.

PMID:
30346709
2.

Delivery of an anti-transthyretin Nanobody to the brain through intranasal administration reveals transthyretin expression and secretion by motor neurons.

Gomes JR, Cabrito I, Soares HR, Costelha S, Teixeira A, Wittelsberger A, Stortelers C, Vanlandschoot P, Saraiva MJ.

J Neurochem. 2018 Jun;145(5):393-408. doi: 10.1111/jnc.14332. Epub 2018 May 9.

3.

Novel half-life extended anti-MIF nanobodies protect against endotoxic shock.

Sparkes A, De Baetselier P, Brys L, Cabrito I, Sterckx YG, Schoonooghe S, Muyldermans S, Raes G, Bucala R, Vanlandschoot P, Van Ginderachter JA, Stijlemans B.

FASEB J. 2018 Jun;32(6):3411-3422. doi: 10.1096/fj.201701189R. Epub 2018 Jan 25.

4.

Protective effect of different anti-rabies virus VHH constructs against rabies disease in mice.

Terryn S, Francart A, Lamoral S, Hultberg A, Rommelaere H, Wittelsberger A, Callewaert F, Stohr T, Meerschaert K, Ottevaere I, Stortelers C, Vanlandschoot P, Kalai M, Van Gucht S.

PLoS One. 2014 Oct 27;9(10):e109367. doi: 10.1371/journal.pone.0109367. eCollection 2014.

5.

Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo.

Maussang D, Mujić-Delić A, Descamps FJ, Stortelers C, Vanlandschoot P, Stigter-van Walsum M, Vischer HF, van Roy M, Vosjan M, Gonzalez-Pajuelo M, van Dongen GA, Merchiers P, van Rompaey P, Smit MJ.

J Biol Chem. 2013 Oct 11;288(41):29562-72. doi: 10.1074/jbc.M113.498436. Epub 2013 Aug 26.

6.

Selection of nanobodies that target human neonatal Fc receptor.

Andersen JT, Gonzalez-Pajuelo M, Foss S, Landsverk OJ, Pinto D, Szyroki A, de Haard HJ, Saunders M, Vanlandschoot P, Sandlie I.

Sci Rep. 2013;3:1118. doi: 10.1038/srep01118. Epub 2013 Jan 23.

7.

Enhancement of polymeric immunoglobulin receptor transcytosis by biparatopic VHH.

Emmerson CD, van der Vlist EJ, Braam MR, Vanlandschoot P, Merchiers P, de Haard HJ, Verrips CT, van Bergen en Henegouwen PM, Dolk E.

PLoS One. 2011;6(10):e26299. doi: 10.1371/journal.pone.0026299. Epub 2011 Oct 14.

8.

Nanobodies® specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion.

Schepens B, Ibañez LI, De Baets S, Hultberg A, Bogaert P, De Bleser P, Vervalle F, Verrips T, Melero J, Vandevelde W, Vanlandschoot P, Saelens X.

J Infect Dis. 2011 Dec 1;204(11):1692-701. doi: 10.1093/infdis/jir622. Epub 2011 Oct 12.

PMID:
21998474
9.

Nanobodies®: new ammunition to battle viruses.

Vanlandschoot P, Stortelers C, Beirnaert E, Ibañez LI, Schepens B, Depla E, Saelens X.

Antiviral Res. 2011 Dec;92(3):389-407. doi: 10.1016/j.antiviral.2011.09.002. Epub 2011 Sep 10. Review.

PMID:
21939690
10.

Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules.

Hultberg A, Temperton NJ, Rosseels V, Koenders M, Gonzalez-Pajuelo M, Schepens B, Ibañez LI, Vanlandschoot P, Schillemans J, Saunders M, Weiss RA, Saelens X, Melero JA, Verrips CT, Van Gucht S, de Haard HJ.

PLoS One. 2011 Apr 1;6(4):e17665. doi: 10.1371/journal.pone.0017665.

11.

Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection.

Ibañez LI, De Filette M, Hultberg A, Verrips T, Temperton N, Weiss RA, Vandevelde W, Schepens B, Vanlandschoot P, Saelens X.

J Infect Dis. 2011 Apr 15;203(8):1063-72. doi: 10.1093/infdis/jiq168.

PMID:
21450996
12.

CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells.

Jähnichen S, Blanchetot C, Maussang D, Gonzalez-Pajuelo M, Chow KY, Bosch L, De Vrieze S, Serruys B, Ulrichts H, Vandevelde W, Saunders M, De Haard HJ, Schols D, Leurs R, Vanlandschoot P, Verrips T, Smit MJ.

Proc Natl Acad Sci U S A. 2010 Nov 23;107(47):20565-70. doi: 10.1073/pnas.1012865107. Epub 2010 Nov 8.

13.

Production, characterization and in vitro testing of HBcAg-specific VHH intrabodies.

Serruys B, Van Houtte F, Farhoudi-Moghadam A, Leroux-Roels G, Vanlandschoot P.

J Gen Virol. 2010 Mar;91(Pt 3):643-52. doi: 10.1099/vir.0.016063-0. Epub 2009 Nov 4.

PMID:
19889923
14.

Llama-derived single-domain intrabodies inhibit secretion of hepatitis B virions in mice.

Serruys B, Van Houtte F, Verbrugghe P, Leroux-Roels G, Vanlandschoot P.

Hepatology. 2009 Jan;49(1):39-49. doi: 10.1002/hep.22609.

PMID:
19085971
15.

Comparison of serum humoral responses induced by oral immunization with the hepatitis B virus core antigen and the cholera toxin B subunit.

Broos K, Janssens ME, De Goeyse I, Vanlandschoot P, Leroux-Roels G, Geysen D, Guisez Y.

Clin Vaccine Immunol. 2008 May;15(5):852-8. doi: 10.1128/CVI.00382-07. Epub 2008 Mar 26.

16.

Expression, purification and characterization of full-length RNA-free hepatitis B core particles.

Broos K, Vanlandschoot P, Maras M, Robbens J, Leroux-Roels G, Guisez Y.

Protein Expr Purif. 2007 Jul;54(1):30-7. Epub 2007 Feb 20.

PMID:
17387023
17.

Inhibition of replication of primary HIV-1 isolates in huPBL-NOD/Scid mice by antibodies from HIV-1 infected patients.

Steyaert S, Heyndrickx L, Verhoye L, Vermoesen T, Donners H, Fransen K, Van Wanzeele F, Vandergucht B, Vanham G, Leroux-Roels G, Vanlandschoot P.

Antiviral Res. 2007 Aug;75(2):129-38. Epub 2007 Mar 6.

PMID:
17379323
18.

The intraspleen huPBL NOD/SCID model to study the human HIV-specific antibody response selected in the course of natural infection.

Steyaert S, Verhoye L, Beirnaert E, Donners H, Fransen K, Heyndrickx L, Vanham G, Leroux-Roels G, Vanlandschoot P.

J Immunol Methods. 2007 Mar 30;320(1-2):49-57. Epub 2007 Jan 9.

PMID:
17258763
19.

Contamination of a recombinant hepatitis B virus nucleocapsid preparation with a human B-cell activator.

Vanlandschoot P, Van Houtte F, Serruys B, Leroux-Roels G.

J Virol. 2007 Mar;81(5):2535-6. Epub 2006 Dec 6. No abstract available.

20.

The role of heparan sulfate and TLR2 in cytokine induction by hepatitis B virus capsids.

Vanlandschoot P, Leroux-Roels G.

J Immunol. 2005 Nov 15;175(10):6253; author reply 6253-5. No abstract available.

21.

Human hepatocytes secrete soluble CD14, a process not directly influenced by HBV and HCV infection.

Meuleman P, Steyaert S, Libbrecht L, Couvent S, Van Houtte F, Clinckspoor F, de Hemptinne B, Roskams T, Vanlandschoot P, Leroux-Roels G.

Clin Chim Acta. 2006 Apr;366(1-2):156-62. Epub 2005 Oct 25.

PMID:
16253217
22.

Immunostimulatory potential of hepatitis B nucleocapsid preparations: lipopolysaccharide contamination should not be overlooked.

Vanlandschoot P, Van Houtte F, Ulrichts P, Tavernier J, Leroux-Roels G.

J Gen Virol. 2005 Feb;86(Pt 2):323-31.

PMID:
15659751
23.
24.

A temperature-dependent inhibitory activity of serum on the capacity of Saccharomyces cerevisiae-derived hepatitis B surface antigen to bind to monocytes.

Vanlandschoot P, Van Houtte F, Roobrouck A, Stelter F, Gavilanes F, Leroux-Roels G.

Arch Virol. 2005 Feb;150(2):247-59. Epub 2004 Oct 11.

PMID:
15480855
25.

The nucleocapsid of the hepatitis B virus: a remarkable immunogenic structure.

Vanlandschoot P, Cao T, Leroux-Roels G.

Antiviral Res. 2003 Oct;60(2):67-74. Review.

PMID:
14638400
26.

Soluble CD14 levels are increased and inversely correlated with the levels of hepatitis B surface antigen in chronic hepatitis B patients.

Steyaert S, Vanlandschoot P, Van Vlierberghe H, Diepolder H, Leroux-Roels G.

J Med Virol. 2003 Oct;71(2):188-94.

PMID:
12938192
27.

A simple and rapid method to determine the zygosity of uPA-transgenic SCID mice.

Meuleman P, Vanlandschoot P, Leroux-Roels G.

Biochem Biophys Res Commun. 2003 Aug 22;308(2):375-8.

PMID:
12901879
28.

Saccharomyces cerevisiae-derived HBsAg preparations differ in their attachment to monocytes, immune-suppressive potential, and T-cell immunogenicity.

Vanlandschoot P, Van Houtte F, Hoek F, Nieuwland R, Leroux-Roels G.

J Med Virol. 2003 Aug;70(4):513-9.

PMID:
12794712
29.

Viral apoptotic mimicry: an immune evasion strategy developed by the hepatitis B virus?

Vanlandschoot P, Leroux-Roels G.

Trends Immunol. 2003 Mar;24(3):144-7. Review.

PMID:
12615210
30.

Characterization of HLA DR13-restricted CD4(+) T cell epitopes of hepatitis B core antigen associated with self-limited, acute hepatitis B.

Cao T, Desombere I, Vanlandschoot P, Sällberg M, Leroux-Roels G.

J Gen Virol. 2002 Dec;83(Pt 12):3023-33.

PMID:
12466479
31.

Recombinant HBsAg, an apoptotic-like lipoprotein, interferes with the LPS-induced activation of ERK-1/2 and JNK-1/2 in monocytes.

Vanlandschoot P, Roobrouck A, Van Houtte F, Leroux-Roels G.

Biochem Biophys Res Commun. 2002 Sep 27;297(3):486-91.

PMID:
12270119
32.

LPS-binding protein and CD14-dependent attachment of hepatitis B surface antigen to monocytes is determined by the phospholipid moiety of the particles.

Vanlandschoot P, Van Houtte F, Roobrouck A, Farhoudi A, Stelter F, Peterson DL, Gomez-Gutierrez J, Gavilanes F, Leroux-Roels G.

J Gen Virol. 2002 Sep;83(Pt 9):2279-89.

PMID:
12185283
33.

Hepatitis B virus surface antigen suppresses the activation of monocytes through interaction with a serum protein and a monocyte-specific receptor.

Vanlandschoot P, Van Houtte F, Roobrouck A, Farhoudi A, Leroux-Roels G.

J Gen Virol. 2002 Jun;83(Pt 6):1281-9.

PMID:
12029142
34.

Prevention of hepatitis B infections: vaccination and its limitations.

Leroux-Roels G, Cao T, De Knibber A, Meuleman P, Roobrouck A, Farhoudi A, Vanlandschoot P, Desombere I.

Acta Clin Belg. 2001 Jul-Aug;56(4):209-19. Review.

PMID:
11603250
35.

Hepatitis B virus core antigen binds and activates naive human B cells in vivo: studies with a human PBL-NOD/SCID mouse model.

Cao T, Lazdina U, Desombere I, Vanlandschoot P, Milich DR, Sällberg M, Leroux-Roels G.

J Virol. 2001 Jul;75(14):6359-66.

36.

A universal influenza A vaccine based on the extracellular domain of the M2 protein.

Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W.

Nat Med. 1999 Oct;5(10):1157-63.

PMID:
10502819
37.

Protection of mice against a lethal influenza virus challenge after immunization with yeast-derived secreted influenza virus hemagglutinin.

Saelens X, Vanlandschoot P, Martinet W, Maras M, Neirynck S, Contreras R, Fiers W, Jou WM.

Eur J Biochem. 1999 Feb;260(1):166-75.

38.

Evaluation of recombinant A/Victoria/3/75 (H3N2) influenza neuraminidase mutants as potential broad-spectrum subunit vaccines against influenza A.

Martinet W, Deroo T, Saelens X, Beirnaert E, Vanlandschoot P, Contreras R, Fiers W, Min Jou W.

Arch Virol. 1998;143(10):2011-9.

PMID:
9856088
39.

An antibody which binds to the membrane-proximal end of influenza virus haemagglutinin (H3 subtype) inhibits the low-pH-induced conformational change and cell-cell fusion but does not neutralize virus.

Vanlandschoot P, Beirnaert E, Barrère B, Calder L, Millar B, Wharton S, Jou WM, Fiers W.

J Gen Virol. 1998 Jul;79 ( Pt 7):1781-91.

PMID:
9680143
40.

pH-dependent aggregation and secretion of soluble monomeric influenza hemagglutinin.

Vanlandschoot P, Beirnaert E, Grooten J, Jou WM, Fiers W.

Arch Virol. 1998;143(2):227-39.

PMID:
9541609
41.

Molecular and immunological characterization of soluble aggregated A/Victoria/3/75 (H3N2) influenza haemagglutinin expressed in insect cells.

Vanlandschoot P, Beirnaert E, Neirynck S, Saelens X, Jou WM, Fiers W.

Arch Virol. 1996;141(9):1715-26.

PMID:
8893793
42.

A fairly conserved epitope on the hemagglutinin of influenza A (H3N2) virus with variable accessibility to neutralizing antibody.

Vanlandschoot P, Beirnaert E, Dewilde S, Saelens X, Bestebroer T, De Jong J, Jou WM, Fiers W.

Virology. 1995 Oct 1;212(2):526-34.

43.

Recombinant secreted haemagglutinin protects mice against a lethal challenge of influenza virus.

Vanlandschoot P, Maertens G, Jou WM, Fiers W.

Vaccine. 1993 Sep;11(12):1185-7.

PMID:
8256499

Supplemental Content

Loading ...
Support Center